Core Viewpoint - A class action securities lawsuit has been filed against RxSight, Inc. alleging securities fraud that negatively impacted investors between November 7, 2024, and July 8, 2025 [1][2]. Group 1: Lawsuit Details - The lawsuit claims that RxSight, Inc. faced "adoption challenges" and structural issues leading to declines in sales and utilization [2]. - It is alleged that the defendants overstated the demand for RxSight's products, which resulted in the company being unlikely to meet its previously issued financial guidance for fiscal year 2025 [2]. - The positive statements made by the defendants regarding the company's business and prospects were claimed to be materially misleading and lacked a reasonable basis [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until September 22, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [3]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [3]. Group 3: Firm Background - Levi & Korsinsky, LLP has a history of securing hundreds of millions of dollars for shareholders and has been recognized as one of the top securities litigation firms in the United States for seven consecutive years [4].

Financial Data and Key Metrics Changes - The company has cut its guidance by approximately 35% since January, now implying nearly a 30% year-over-year decline in sales for 2025 [2][3] - The overall cataract procedure market has seen a drop, with Q1 marking the first actual decline in total procedures experienced in a long time, leading to subpar growth in Q2 [3][4] Business Line Data and Key Metrics Changes - The premium IOL market, which is a specific submarket for the company, has remained relatively flat, with most growth in recent years attributed to the LAL [3][4] - The company has focused on same-store sales growth due to slower growth in recent customer cohorts, affecting ROI calculations for new customers [5][6] Market Data and Key Metrics Changes - The premium IOL market is approximately 50% toric lenses, which are lower-priced options, indicating a potential trade-down by consumers [13][14] - The overall market has shrunk, with competitors also experiencing declines, except for the company which has seen some growth [14] Company Strategy and Development Direction - The company is refocusing on internal factors that can be controlled, particularly on increasing LAL utilization among existing customers [5][6] - A reorganization has been implemented to align the LAL sales team and clinical team under the same management to improve efficiency and drive growth [24][25] Management Comments on Operating Environment and Future Outlook - Management acknowledges that the current environment has not changed significantly and remains cautious about the second half of the year, expecting conservative growth [16][18] - The company aims for sequential growth rather than year-over-year comparisons, focusing on LAL sales as a key growth driver [29][30] Other Important Information - The company has adequate cash to reach profitability, with a significant portion of operating expenses attributed to non-cash stock-based compensation [59] - The company is optimistic about the future of LAL technology, emphasizing its unique advantages over competitors [60] Q&A Session Summary Question: What is the outlook for the business given the recent guidance cuts? - Management indicated that the guidance reflects a conservative outlook due to both macroeconomic factors and internal challenges, with a focus on improving same-store sales growth [2][16] Question: How is the company addressing competition in the premium IOL market? - Management noted that while competition has increased, the unique adjustability of their LAL product provides a significant advantage over fixed lenses [22][39] Question: What are the expectations for international market growth? - Management expects modest contributions from international markets in 2026, with a focus on developing KOLs and local clinical data [51][52]

Core Points - The Gross Law Firm has issued a notice to shareholders of RxSight, Inc. regarding a class action lawsuit due to alleged misleading statements and undisclosed issues affecting the company's performance [1][2] - The class period for the lawsuit is from November 7, 2024, to July 8, 2025, during which the company reportedly faced "adoption challenges" and structural issues leading to declines in sales and utilization [1] - Allegations include overstated demand for RxSight's products and the likelihood of the company failing to meet its financial guidance for fiscal year 2025 [1] Company and Industry Summary - The lawsuit claims that the defendants made materially false and misleading statements about RxSight's business operations and prospects, which misled investors [1] - Shareholders are encouraged to register for the class action by September 22, 2025, to potentially become lead plaintiffs and participate in recovery efforts [2] - The Gross Law Firm emphasizes its commitment to protecting investors' rights and ensuring companies adhere to responsible business practices [3]

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., and investors have until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - A further revenue forecast cut occurred on July 8, 2025, due to slower LAL utilization and adoption challenges, resulting in another 38% decline in stock price, from $12.79 to $7.95 per share [6].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of RxSight, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the lawsuit is from November 7, 2024, to July 8, 2025, inclusive [1]. - Investors who purchased RxSight securities during this period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by September 22, 2025 [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors, showcasing its capability in recovering significant amounts for its clients [3]. Group 3: Case Allegations - The lawsuit alleges that RxSight made false and misleading statements regarding its business, including claims of "adoption challenges" and overstated demand for its products [4]. - It is claimed that these misrepresentations led to RxSight being unlikely to meet its previously issued financial guidance for fiscal year 2025 [4]. - The lawsuit asserts that when the true details about RxSight's performance became known, investors suffered damages [4].

NEW YORK, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. Should You Join This Class Action Lawsuit? Do you, or did you, own shares of RxSight, Inc. (NASDAQ: RXST)?Did you purchase your shares between November 7, 2024 and July 8, 2025, inclusive?Did you lose money in you ...

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is pending in the U.S. District Court for the Central District of California, titled Makaveev v. RxSight, Inc., et al., No. 25-cv-01596, with investors having until September 22, 2025, to seek lead plaintiff status [2]. Group 3: Financial Performance and Stock Impact - RxSight experienced a slowdown in LAL utilization, first noted in 2024, which was not disclosed to investors, leading to a significant stock price decline [4]. - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, resulting in a 38% drop in stock price from $26.12 to $16.21 per share [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, caused another 38% decline in stock price from $12.79 to $7.95 per share [6].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Issues - The lawsuit claims violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors who purchased RxSight securities [2]. - The complaint highlights that RxSight failed to disclose "adoption challenges" and experienced a slowdown in LAL utilization, first noted in 2024 [4]. Group 3: Stock Performance - On April 3, 2025, RxSight cut its 2025 full-year revenue forecast, leading to a stock price drop of approximately 38%, from $26.12 to $16.21 per share [5]. - Following another revenue forecast cut on July 8, 2025, the stock price fell roughly 38% again, from $12.79 to $7.95 per share [6].

Core Viewpoint - A lawsuit has been filed against RxSight, Inc. and its senior executives for potential violations of federal securities laws, with claims related to undisclosed challenges in product adoption and a significant decline in stock value following revenue forecast cuts [1][2][4][5][6]. Group 1: Company Overview - RxSight, Inc. specializes in manufacturing light adjustable intraocular lenses for cataract surgery, with its primary product being the Light Adjustable Lens (LAL) that can be customized post-surgery through non-invasive light treatments [3]. Group 2: Legal Proceedings - The lawsuit is filed in the U.S. District Court for the Central District of California, with investors having until September 22, 2025, to seek lead plaintiff status [2]. - The complaint alleges violations under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased RxSight securities [2]. Group 3: Financial Impact - On April 3, 2025, RxSight reduced its 2025 full-year revenue forecast, citing a market softening that began in the second half of 2024, leading to a stock price drop of approximately 38% from $26.12 to $16.21 [5]. - A further revenue forecast cut on July 8, 2025, attributed to slower LAL utilization and adoption challenges, resulted in another 38% decline in stock price from $12.79 to $7.95 [6].

NEW YORK, Aug. 26, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in RxSight, Inc. ("RxSight, Inc." or the "Company") (NASDAQ: RXST) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of RxSight, Inc. investors who were adversely affected by alleged securities fraud between November 7, 2024 and July 8, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rxsight-inc-lawsuit-submis ...